What the FDA labels say about taking them together
Azacitidine and eltrombopag
Eltrombopag's FDA label of December 18, 2025 names azacitidine in its warnings and precautions section; the azacitidine labels PlainMeds reads (3) do not name eltrombopag. The eltrombopag label: “… intermediate-1, intermediate-2 or high risk MDS with thrombocytopenia, receiving azacitidine in combination with either PROMACTA (n = 179) or placebo (n = 177) was terminated due to lack of efficacy and safety reasons …”
Check it at the source: the azacitidine FDA label on DailyMed (effective January 29, 2024, Celgene Corporation); the eltrombopag FDA label on DailyMed (effective December 18, 2025, Novartis Pharmaceuticals Corporation).
What does the azacitidine label say about eltrombopag?
Azacitidine's label (effective January 29, 2024) and its 2 other brand-application labels do not name eltrombopag in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (VIDAZA), NDA050794 (Bristol-Myers), as published by Celgene Corporation, effective January 29, 2024 (SPL set 3495a71a-cc04-4776-851f-f185956f32af), via openFDA; the full label on DailyMed
What does the eltrombopag label say about azacitidine?
Eltrombopag label, warnings and precautionsRisk of Death and Progression of Myelodysplastic Syndromes to Acute Myeloid Leukemia A randomized, double-blind, placebo-controlled, multicenter trial in patients with International Prognostic Scoring System (IPSS) intermediate-1, intermediate-2 or high risk MDS with thrombocytopenia, receiving azacitidine in combination with either PROMACTA (n = 179) or placebo (n = 177) was terminated due to lack of efficacy and safety reasons, including increased progression to acute myeloid leukemia (AML).
Source: FDA drug label (PROMACTA), Novartis Pharmaceuticals Corporation, effective December 18, 2025 (SPL set 7714a0ed-34bb-46e6-a0a5-b363908b22c2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Azacitidine | Eltrombopag | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Anemia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $25.85 per tablet 50 mg tablet |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once